The estimated Net Worth of Jean Luc M Lemercier is at least $14.7 Milione dollars as of 3 May 2024. Mr. Lemercier owns over 4,157 units of Edwards Lifesciences Corp stock worth over $12,146,316 and over the last 7 years he sold EW stock worth over $0. In addition, he makes $2,509,200 as Corporate Vice President - EMEA (Europe e Middle East and Africa) at Edwards Lifesciences Corp.
Jean has made over 27 trades of the Edwards Lifesciences Corp stock since 2018, according to the Form 4 filled with the SEC. Most recently he exercised 4,157 units of EW stock worth $283,715 on 3 May 2024.
The largest trade he's ever made was exercising 20,523 units of Edwards Lifesciences Corp stock on 1 February 2021 worth over $267,209. On average, Jean trades about 5,427 units every 51 days since 2018. As of 3 May 2024 he still owns at least 177,968 units of Edwards Lifesciences Corp stock.
You can see the complete history of Mr. Lemercier stock trades at the bottom of the page.
Jean-Luc Lemercier serves as Corporate Vice President - EMEA (Europe, Middle East and Africa) of the Company. Mr. Lemercier has been Corporate Vice President, EMEA (Europe, Middle East and Africa), Canada and Latin America since July 2017. Prior to assuming his current role, Mr. Lemercier served as Vice President of Transcatheter Heart Valves EMEA from 2008 to 2017. Under his leadership, Edwards has successfully built its leadership position in Europe. Before joining Edwards, Mr. Lemercier served in various leadership roles with Johnson & Johnson Cordis from 1996 to 2008, including leader of the structural heart disease group in the United States; Vice President of New Business Development in Europe; Vice President of the Cordis Cardiology Division in Belgium; and General Manager of Cordis France. Mr. Lemercier has more than 30 years of medical technology experience, beginning with Baxter in France, and held several sales and marketing management positions within Baxter Europe and the United States. Mr. Lemercier has served on the Board of CARMAT since January 2017.
As the Corporate Vice President - EMEA (Europe e Middle East and Africa) of Edwards Lifesciences Corp, the total compensation of Jean Lemercier at Edwards Lifesciences Corp is $2,509,200. There are 5 executives at Edwards Lifesciences Corp getting paid more, with Michael Mussallem having the highest compensation of $11,521,000.
Jean Lemercier is 62, he's been the Corporate Vice President - EMEA (Europe e Middle East and Africa) of Edwards Lifesciences Corp since 2017. There are 9 older and 10 younger executives at Edwards Lifesciences Corp. The oldest executive at Edwards Lifesciences Corp is William Link, 74, who is the Independent Director.
Jean's mailing address filed with the SEC is ONE EDWARDS WAY, , IRVINE, CA, 92614.
Over the last 21 years, insiders at Edwards Lifesciences Corp have traded over $94,964,396 worth of Edwards Lifesciences Corp stock and bought 47,398 units worth $3,992,090 . The most active insiders traders include Michael A Mussallem, Donald E Jr Bobo e Steven R Loranger. On average, Edwards Lifesciences Corp executives and independent directors trade stock every 8 days with the average trade being worth of $1,126,057. The most recent stock trade was executed by Donald E Jr Bobo on 11 September 2024, trading 5,000 units of EW stock currently worth $226,400.
edwards lifesciences (nyse: ew) is the global leader in the science of heart valves and hemodynamic monitoring. driven by a passion to help patients, the company partners with clinicians to develop innovative technologies in the areas of structural heart disease and critical care monitoring that save and enhance lives. headquartered in irvine, california, edwards lifesciences has extensive operations in north america, europe, japan, latin america and asia and currently employs about 6,400 individuals worldwide. for us, helping patients is not a slogan – it's our life’s work. from developing devices that replace or repair a diseased heart valve to creating new technologies that monitor vital signs in the critical care setting, we help ensure that patients regain and even improve their quality of life.
Edwards Lifesciences Corp executives and other stock owners filed with the SEC include: